Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial

Journal:
Nature Medicine
Published:
Affiliations:
20
Authors:
22
Institutions Authors Share
AstraZeneca United States, United States of America (USA)
4.000000
0.18
AstraZeneca Cambridge, United Kingdom (UK)
3.000000
0.14
NIH National Institute of Allergy and Infectious Diseases (NIAID), United States of America (USA)
2.000000
0.09
AstraZeneca Sweden, Sweden
2.000000
0.09
Rainbow Babies & Children's Hospital, United States of America (USA)
1.000000
0.05
Brussels University Hospital (H.U.B), Belgium
1.000000
0.05
University of California, San Diego (UC San Diego), United States of America (USA)
1.000000
0.05
Medical University of Lodz (MUL), Poland
1.000000
0.05
University Medical Centre Mannheim (UMM) at Medical Faculty Mannheim, Uni Heidelberg, Germany
1.000000
0.05
Chiba Aoba Municipal Hospital, Japan
1.000000
0.05
Erasmus University Medical Center (Erasmus MC), Netherlands
1.000000
0.05
AstraZeneca Poland, Poland
1.000000
0.05
University of Versailles Saint-Quentin-en-Yvelines (UVSQ), France
0.500000
0.02
Foch Hospital, France
0.500000
0.02
NIHR Imperial Biomedical Research Centre, United Kingdom (UK)
0.500000
0.02
Guy's and St Thomas' NHS Foundation Trust, United Kingdom (UK)
0.500000
0.02
Haihe Laboratory of Cell Ecosystem, China
0.500000
0.02
Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, China
0.500000
0.02